Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2022

View Archived Issues

New free fatty acid receptor 1 agonists identified at Rezubio Pharmaceuticals

Shanghai Zheye Biotechnology describes new anticancer compounds

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent TLR7/8/9 antagonists

Apoptosis regulator Bcl-2 inhibitors discovered at Beijing Innocare Medical Technology

China Hinye Pharmaceutical presents prodrugs of the active metabolite of clopidogrel

Mouse model of SARS-CoV-2 infection shows COVID-19-like disease is dependent on ACE2

STING signaling in beta cells maintains glucose homeostasis

Type II interferon restricts severity of NMO in a new preclinical model

Bryostatin-1 promotes regenerative phenotype within microglia and CNS macrophages

Novel murine model developed to test CNS-penetrant BTK inhibitors

BAFF biomarker tied to severity of allergic rhinitis

Shionogi and Ube collaborate to advance S-337395 toward clinic for RSV

Study identifies potential new bone disease target

Murine model reveals aging to promote autoimmune encephalomyelitis with meningeal inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...